Login to Your Account

Super-fast approval for Genentech's 2nd-line ALK inhibitor in NSCLC

By Jennifer Boggs
Managing Editor

Friday, December 11, 2015

Barely three months after accepting a new drug application for Genentech Inc's Alecensa, the FDA granted accelerated approval to the breakthrough therapy-designated drug for treating ALK-positive NSCLC patients who have progressed or are intolerant to Xalkori.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription